Japan Recommends Donanemab, Sets Raft Of New And Reduced Prices
Dupixent, Tezspire Slashed
A Japanese approval for Lilly's Alzheimer's drug donanemab is expected soon following a positive recommendation from the MHLW. The ministry has also announced reimbursement prices for 12 new products including Fabhalta, along with price cuts for Tezspire, Dupixent and competitors following a review.
